

Working Together Toward a TB-Free Ukraine

Johnson & Johnson is collaborating with the Government of Ukraine and other partners to comprehensively address the challenge of multidrug-resistant tuberculosis in Ukraine



THE CHALLENGE

Ukraine is one of the 30 countries with the highest multidrug-resistant TB (MDR-TB) burdens and second in Europe in TB mortality rate.¹

According to the World Health Organization (WHO), there are about 32,000 Ukrainians registered with TB, 4,000 of whom are MDR-TB patients.² Approximately one in five people living with TB are co-infected with HIV.

To make TB history in Ukraine and around the world, it will be essential to accelerate the development and delivery of new innovations and creative solutions to help reach more patients.

ACTION TO END TB IN UKRAINE

The government of Ukraine is committed to making progress towards achieving the goals of the Tuberculosis Action Plan for the End TB Strategy. In 2018, Ukraine implemented a new approach to TB control aimed at improving detection, treatment and financing of tuberculosis health-care services. Moreover, Ukraine adopted WHO-recommended guidelines to improve early detection and treatment. In early 2021, Ukraine began actively switching to an outpatient TB treatment model involving primary care health care providers (HCPs) in TB management.

Johnson & Johnson collaborated with key stakeholders – including the Ministry of Health, local patient advocacy groups and international partners – to broaden Ukrainian patients' access to innovative therapy to improve their lives. In 2017, Johnson & Johnson introduced our antibiotic for pulmonary multidrug-resistant TB (MDR-TB) in Ukraine, which was the first TB medicine with a novel mechanism of action to be introduced in the country in more than 40 years. From 2015-2019, Johnson & Johnson provided our MDR-TB medicine through a four-year donation program to support patient access in low- and middle-income countries (LMICs), including Ukraine. Today our medicine is available to Ukraine at a not-for-profit price both through the Stop TB Partnership's Global Drug Facility (GDF) and via local procurement.

Additionally, Johnson & Johnson has supported efforts to strengthen healthcare delivery systems by training health workers, improving diagnostic capacity and supporting efforts to raise awareness and reduce stigma around TB at the community level. Beyond this, the Company is accelerating TB research and development (R&D) to discover innovative next-generation treatments and other tools that will be needed to reach the global goal of ending TB.

These efforts are part of a comprehensive 10-year TB initiative launched by Johnson & Johnson in September 2018 focused on treatment access, patient finding and R&D.

GLOBAL JOHNSON & JOHNSON TB PROGRAM AT A GLANCE



First novel medicine for TB in more than **40 years**; approved in **70 countries**



474K courses of treatment delivered for MDR-TB patients in **153 countries**, including the 30 highest-burden countries (as of March 2022)



Donating **105K** courses of treatment to eligible countries through a **four-year donation** program with USAID and JSC Pharmstandard, implemented through the Stop TB Partnership's Global Drug Facility


jnj.com/TB

1. Tuberculosis surveillance and monitoring in Europe 2019 (2017 data)

2. WHO. Global TB Report 2021. URL: <https://www.who.int/publications-detail/global-tb-report-2021>. Last Accessed: 14 October 2021

COLLABORATING AT EVERY LEVEL

Johnson & Johnson is working with the Government of Ukraine and other partners to take a holistic approach to ending TB by accelerating affordable access to treatment, supporting health systems strengthening efforts, raising awareness and reducing stigma around TB among the general public, as well as driving cutting-edge research and development.



ACCESS

Provided our MDR-TB treatment free-of-charge to patients in eligible LMICs, including Ukraine, through a four-year donation program (2015-2019); starting in 2019, providing access at a not-for-profit price via the GDF and local procurement.




APPROPRIATE USE

Growing and consolidating private-public efforts for TB elimination by signing an MOU with the Center of Public Health under the Ministry of Health of Ukraine in May 2019.



MEDICAL EDUCATION

Supporting the training of more than 3,300 TB healthcare professionals to date in MDR-TB clinical management. Preparing to support HCPs on primary care level of TB management starting in 2022.



DETECTION & TESTING

Improving case finding and strengthening health systems to reach the thousands of people with undiagnosed TB and MDR-TB and connect them to care by increasing diagnostic capacity, training health workers and raising community awareness, while also providing expertise and solutions in MDR-TB patients' healthcare pathway.



PARTNERSHIP

Collaborating through conferences, seminars, training and research activities, and exchanging scientific and medical information. Launched the DR-TB Lifeline Quickfire Challenge to identify and fund innovative solutions for continuity of DR-TB care during COVID-19. A non-commercial organization "TBpeopleUkraine" was one of five winners.

ABOUT J&J GLOBAL PUBLIC HEALTH

Through a dedicated global public health (GPH) organization that combines R&D, global access strategies and programs, and local operations, Johnson & Johnson is putting the world's most vulnerable and underserved at the heart of everything we do—measuring our success in lives improved. As a team of innovators, we are committed to pioneering and sustainably delivering meaningful and transformation products. Upholding the rich heritage of Johnson & Johnson, we are taking on the toughest challenges, and, ultimately, we hope to do our part to close the gap of inequity and pave the way to a healthier future for the world's most vulnerable and underserved populations.



jnj.com/global-public-health



@JNJGlobalHealth



gph@its.jnj.com